Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Inclusion Criteria: * Age 18 years or older * Confirmed CD20 positive WM, according to the recommendations of the 2nd Workshop on WM. * Presence of at least one criterion for initiation of therapy, according to the 2nd Workshop on WM. * Recurrent fever, night sweats, weight loss, fatigue * Hyperviscosity * Lympadenopathy which is either symptomatic or bulky more or equal to 5cm in maximum diameter * Symptomatic hepatomegaly and/or splenomegaly * Symptomatic organomegaly and/or organ or tissue infiltration * Peripheral neuropathy due to WM * Symptomatic cryoglobulinemia * Cold agglutinin anemia * Immune hemolytic anemia and/or thrombocytopenia * Nephropathy related to WM * Amyloidosis related to WM * Hemoglobin less or equal than 10g dL * Platelet count less than 100 109 L * Prior treatment for WM comprising at least one regimen containing a therapeutic anti CD20 monoclonal antibody rituximab administered for more or equal than 2 doses of antibody treatment and or a therapeutic chemotherapy, alkylating agent, purine analogue, bendamustine administered for more or equal than 2 cycles of treatment * Patients may be either relapsing progressing at least 6 months after the last administration of first line or subsequent treatment or refractory progressing on or within 6 months of first line or subsequent treatment * Number of prior regimens per lines 1 to 3 * Life expectancy more than 3 months. * ECOG less or equal than 2. * Meet the following pretreatment laboratory criteria at …